Multi-cytokine Profiles After Tuberculosis Antigen Stimulation: A Search For New Biomarkers For Latent And Active Tuberculosis
Marc A. Frahm(Duke University), Jason E. Stout(Duke University), Kouros Owzar(Duke University), Guido Ferrari(Duke University), Emily Cadogan(Duke Medical Center), Emily J. Hecker(Duke University), Payam Nahid(University of California, San Francisco), Ann Mosher(Case Western Reserve University), Neela D. Goswami(Centers for Disease Control and Prevention)
Cited by 1
Related Papers
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
|New England Journal of Medicine|2021|548